Our Science

Developing select technologies

Explore Arch Biopartners platforms, teams and publications

Arch Biopartners is a leader in developing novel drugs to treat acute organ inflammation.

Phase I and Phase II clinical trials (2020-21) have led to the company’s lead drug candidate, LSALT Peptide (Metablok), being the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a multi-centre adaptive, randomized, open-label, controlled clinical trial involving fifty-five hospitals across Canada.
  • In 2019 Arch scientists described a novel mechanism of action for organ inflammation in the journal Cell.
  • Arch scientists have identified the enzyme dipeptidase-1 (DPEP1) as a major neutrophil (white blood cell) adhesion receptor in the lungs, kidneys and liver.
  • DPEP1 was shown to be the target of LSALT Peptide (Metablok), the Company’s lead drug candidate targeting inflammation in the lungs and kidneys.
Additional programs under development:
  • AB569, a potential new treatment for antibiotic resistant bacterial wound infections; and,
  • ‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.
The company is led by experienced groups of scientists with an executive, board and advisors with scientific, pharmaceutical, biotechnology and corporate financial experience.
Science and Research Teams
  • Metablok is led by Dr. Stephen Robbins Ph. D., Dr. Donna Senger Ph. D. and Jennifer Rahn B Sc., M Sc. at the University of Calgary
  • AB569 was led by Dr. Daniel J. Hassett Ph. D. at the University of Cincinnati, College of Medicine until his passing in 2022.
  • BORG Peptide is led by Dr. Randall Irvin Ph. D., Dr. Dongyang Li Ph. D. and Dr. Elisabeth Davis Ph. D. at the University of Alberta
  • The Treatments for Inflammation team is led by Dr. Daniel Muruve Ph. D., Dr. Justin Macdonald Ph. D., Dr. Paul Beck and Dr. Arthur Lau Ph. D at the University of Calgary
The Arch Biopartners Science Teams have all participated and authored key papers and journal publications as a core part of their ongoing scientific research, discoveries and development.
  • Treatments for Inflammation publications surrounding the development of LSALT Peptide (Metablok) as a treatment for inflammation with broad application to prevent organ and tissue injury
  • AB569 publications describing AB569 as a novel bactericidal treatment for treatment resistant bacteria and Respiratory Pseudomonas
  • BORG Peptide publications discussing a peptide-based biological coating for enhanced corrosion resistance, strength and control of adhesion of bacteria and microbes.
  • Brain Tumor Stem Cell Targeting publications describe the development of a peptide-based delivery platform for targeting malignant brain tumors

Latest Scientific Publications

Publications Archives